Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mantle-cell lymphoma.

E Campo1, M Raffeld, E S Jaffe

  • 1Hematopathology Section, Hospital Clinic, University of Barcelona, Spain.

Seminars in Hematology
|May 13, 1999
PubMed
Summary
This summary is machine-generated.

Mantle-cell lymphoma (MCL) is a B-cell cancer characterized by cyclin D1 overexpression. This aggressive disease often presents in elderly males with advanced symptoms and poor treatment response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Best practices to reduce microbial contamination during media-fill testing process in hospital pharmacies: a scoping review of literature.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2025
Same author

Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target.

Nature communications·2025
Same author

Fungal Planet description sheets: 1781-1866.

Persoonia·2025
Same author

Perceived relevance of Planetary Health for Medical Students in Italy: Results from a mixed-methods analysis.

Public health in practice (Oxford, England)·2025
Same author

Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.

British journal of haematology·2023
Same author

Scientific AI in Materials Science: a Path to a Sustainable and Scalable Paradigm.

Machine learning: science and technology·2021
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Mantle-cell lymphoma (MCL) is a B-cell lymphoproliferative disorder originating from naive pregerminal center cells.
  • It is characterized by atypical lymphoid cell proliferation, CD5 coexpression, and often presents with nodular or diffuse growth patterns.
  • Two cytologic variants, typical and blastic, exist, with blastic variants exhibiting higher proliferative activity and more aggressive clinical behavior.

Purpose of the Study:

  • To describe the key characteristics, genetic underpinnings, and clinical presentation of Mantle-cell lymphoma (MCL).
  • To highlight the diagnostic significance of cyclin D1 overexpression in MCL.
  • To discuss the genetic alterations and clinical evolution associated with aggressive MCL variants.

Main Methods:

Related Experiment Videos

  • Review of existing literature and case studies on Mantle-cell lymphoma.
  • Analysis of cytological, immunophenotypic, and genetic features of MCL.
  • Correlation of genetic alterations with clinical presentation and prognosis.

Main Results:

  • MCL is characterized by 11q13 translocations and bcl-1 rearrangement, leading to cyclin D1 overexpression, a highly specific marker for MCL.
  • Blastic variants show increased proliferation and aggressive clinical course, often associated with p53 and p16INK4a inactivation.
  • MCL typically affects elderly males with advanced disease, extranodal involvement (bone marrow, GI tract, spleen), and poor response to conventional therapies.

Conclusions:

  • Cyclin D1 is a crucial diagnostic marker for Mantle-cell lymphoma.
  • Aggressive variants of MCL possess distinct genetic alterations and a poorer prognosis.
  • Improved therapeutic strategies are needed for effective management of MCL patients, given the current limitations in treatment efficacy and survival rates.